{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T18:40:11Z","timestamp":1752000011444,"version":"3.41.2"},"reference-count":7,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,8]]},"DOI":"10.7759\/cureus.87536","type":"journal-article","created":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T18:24:33Z","timestamp":1751999073000},"source":"Crossref","is-referenced-by-count":0,"title":["Interstitial Lung Disease as a Herald of P-ANCA Vasculitis: A Case of Evolving Multisystem Disease"],"prefix":"10.7759","author":[{"given":"Tamiru B","family":"Berake","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shray","family":"Ambe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lense","family":"Negash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"samuel","family":"Gretz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Babray","family":"Laek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000000217","article-title":"Pulmonary fibrosis in antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: a series of 49 patients and review of the literature","volume":"93","author":"Comarmond C","year":"2014","unstructured":"Comarmond C, Crestani B, Tazi A, et al.. Pulmonary fibrosis in antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: a series of 49 patients and review of the literature. Medicine (Baltimore). 2014, 93:340-9. 10.1097\/MD.0000000000000217","journal-title":"Medicine (Baltimore)"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S284768","article-title":"ANCA associated vasculitis subtypes: recent insights and future perspectives","volume":"15","author":"Austin K","year":"2022","unstructured":"Austin K, Janagan S, Wells M, Crawshaw H, McAdoo S, Robson JC. ANCA associated vasculitis subtypes: recent insights and future perspectives. J Inflamm Res. 2022, 15:2567-82. 10.2147\/JIR.S284768","journal-title":"J Inflamm Res"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics14171849","article-title":"Relapse predictors in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis","volume":"14","author":"Wawrzycka-Adamczyk K","year":"2024","unstructured":"Wawrzycka-Adamczyk K, Korkosz M, Musia\u0142 J, W\u00f3jcik K. Relapse predictors in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Diagnostics (Basel). 2024, 14:1849. 10.3390\/diagnostics14171849","journal-title":"Diagnostics (Basel)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2016111179","article-title":"Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis","volume":"28","author":"Jayne DR","year":"2017","unstructured":"Jayne DR, Bruchfeld AN, Harper L, et al.. Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis. J Am Soc Nephrol. 2017, 28:2756-67. 10.1681\/ASN.2016111179","journal-title":"J Am Soc Nephrol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/art.41773","article-title":"2021 American College of Rheumatology\/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis","volume":"73","author":"Chung SA","year":"2021","unstructured":"Chung SA, Langford CA, Maz M, et al.. 2021 American College of Rheumatology\/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis Rheumatol. 2021, 73:1366-83. 10.1002\/art.41773","journal-title":"Arthritis Rheumatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2023386","article-title":"Avacopan for the treatment of ANCA-associated vasculitis","volume":"384","author":"Jayne DR","year":"2021","unstructured":"Jayne DR, Merkel PA, Schall TJ, Bekker P. Avacopan for the treatment of ANCA-associated vasculitis. N Engl J Med. 2021, 384:599-609. 10.1056\/NEJMoa2023386","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209133","article-title":"EULAR\/ERA-EDTA recommendations for the management of ANCA-associated vasculitis","volume":"75","author":"Yates M","year":"2016","unstructured":"Yates M, Watts RA, Bajema IM, et al.. EULAR\/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016, 75:1583-94. 10.1136\/annrheumdis-2016-209133","journal-title":"Ann Rheum Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/384117-interstitial-lung-disease-as-a-herald-of-p-anca-vasculitis-a-case-of-evolving-multisystem-disease","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T18:24:34Z","timestamp":1751999074000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/384117-interstitial-lung-disease-as-a-herald-of-p-anca-vasculitis-a-case-of-evolving-multisystem-disease"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,8]]},"references-count":7,"URL":"https:\/\/doi.org\/10.7759\/cureus.87536","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7,8]]}}}